(Reuters) – AstraZeneca (AZN.L) enlisted Germany’s IDT Biologika as a contract manufacturer of its COVID-19 vaccine, as Germany and the European Union seek to boost a delayed immunisation campaign.
AstraZeneca said it was looking into options with IDT to speed up output of finished COVID-19 vaccine in the second quarter, and that both companies planned to invest in adding capacity at IDT Biologika’s production site in Dessau, eastern Germany, to go on stream by the end of 2022. That investment would include up to five 2,000-litre bioreactors capable of making tens of millions of doses per month of AstraZeneca’s vaccine...
Germany’s IDT to help make
AstraZeneca’s COVID-19 vaccine
The German government committed to provide Israel with the option of procuring the Covid-19 vaccine being developed by AstraZeneca plc (LSE: AZN), if it is found to be safe and effective ???, the Israeli Embassy in Germany has told “Globes.” The EU has signed an agreement with UK-Swedish company AstraZeneca to reserve 400 million vaccinations, and according to the Israeli Embassy in Berlin, Germany will insist that Israel, which is an associate member of the EU, will be considered part of the EU.
Germany to ensure Israel will receive Covid-19 vaccine
“The EU has an agreement to procure 400 million vaccinations from AstraZeneca and Germany says Israel is part of the EU for this deal….”
German History of Pfizer,
scroll to the left:
Charles F. Erhart (born Karl Erhart)1821–1891, like his cousin, Charles (Karl) Pfizer, he was born in Ludwigsburg, Stuttgart, Baden-Württemberg, Germany.
Son of Karl Frederick Pfizer and Caroline Klotz
Husband of Anna Pfizer
Father of Alice Marguerite Henriette Pfizer; Charles M. Pfizer, Jr; Ann Pfizer; Julius Pfizer; Gustav Pfizer and 2 others
Brother of Frances Erhartburg[1]